Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer

Head and Neck Cancer Clinical Trial

Official title:

Phase II Study Of Celecoxib In Metastatic Differentiated Thyroid Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00061906
• Other study ID #: OSU-0239
• Status: Completed
• Phase: Phase 2
• First received: June 5, 2003
• Last updated: February 10, 2014
• Start date: January 2003
• Est. completion date: June 2006

Study information

• Verified date: February 2014
• Source: Ohio State University Comprehensive Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Celecoxib may stop the growth of thyroid cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth.

PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who have progressive metastatic differentiated thyroid cancer.

Description:

OBJECTIVES:

• Determine the efficacy of celecoxib, in terms of progression-free survival, in patients with progressive metastatic differentiated thyroid carcinoma.

• Correlate cyclooxygenase (COX)-2 protein expression in tumor biopsies by immunohistochemistry with clinical response in patients treated with this drug.

OUTLINE: Patients receive oral celecoxib twice daily beginning on day 1. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 3 additional months of therapy beyond documentation of CR.

Patients are followed at 4-8 weeks.

PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study within approximately 6 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: June 2006
• Est. primary completion date: June 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Histologically confirmed thyroid carcinoma, including 1 of the following subtypes:

• Papillary

• Follicular

• Hurthle cell

• Insular

• Assessable disease, defined by at least 1 of the following:

• Metastatic (including neck lymph nodes) measurable disease

• At least 20 mm by conventional techniques or at least 10 mm by spiral CT scan

• The following are not considered measurable disease:

• Leptomeningeal disease

• Ascites

• Pleural/pericardial effusion

• Lymphangitis cutis/pulmonis

• Abdominal masses that are not confirmed and followed by imaging techniques

• Cystic lesions

• Tumor lesions within a previously irradiated area

• Elevated serum thyroglobulin levels indicating the presence of metastatic disease

• Must have negative thyroglobulin antibodies

• Must have progressive disease within the past year, defined by at least 1 of the following:

• At least 20% increase in serum thyroglobulin levels

• At least 20% increase in the sum of the longest diameter of measurable lesions

• Appearance of at least 1 new lesion

• Failed or ineligible for standard therapy with iodine I 131 and/or surgery

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• ECOG 0-2

Life expectancy

• At least 1 year

Hematopoietic

• Absolute neutrophil count at least 1,000/mm^3

• Platelet count at least 75,000/mm^3

Hepatic

• Bilirubin no greater than 2.0 mg/dL

• AST/ALT no greater than 2 times upper limit of normal

Renal

• Creatinine no greater than 2.0 mg/dL

Cardiovascular

• No symptomatic congestive heart failure

• No unstable angina pectoris

• No uncontrolled cardiac arrhythmia

Gastrointestinal

• No prior symptomatic or complicated peptic ulcer disease by endoscopy within the past 6 months, defined by any of the following conditions:

• Active gastric or duodenal ulcer

• Gastric or duodenal perforation

• Upper gastrointestinal bleeding

Other

• Not pregnant or nursing

• Negative pregnancy test

• No prior allergic reaction to celecoxib or sulfonamides

• No prior urticaria, asthma, or allergic reaction to aspirin or other nonsteroidal anti-inflammatory agents

• No ongoing or active infection

• No psychiatric illness or social situation that would preclude study compliance

• No other uncontrolled concurrent illness that would preclude study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• More than 1 month since prior systemic chemotherapy

Endocrine therapy

• Not specified

Radiotherapy

• See Disease Characteristics

• More than 3 months since prior external beam radiotherapy (unless an indicator lesion is outside the radiation field)

• More than 6 months since prior iodine I 131 therapy

Surgery

• See Disease Characteristics

• More than 1 month since prior surgery

Other

• More than 2 weeks since prior conventional doses of celecoxib or rofecoxib for osteoarthritis, rheumatoid arthritis, or dysmenorrhea

• No concurrent combination antiretroviral therapy for HIV-positive patients

• No other concurrent investigational agents

• No concurrent chronic (more than 1 week of therapy) fluconazole therapy

• Concurrent oral or IV bisphosphonates for bony metastases are allowed

• Concurrent low-dose aspirin (no greater than 325 mg/day) for cardiovascular disease is allowed

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Head and Neck Cancer
• Head and Neck Neoplasms

Intervention

Drug:
• celecoxib
Treatment will be administered on an outpatient basis. Oral celecoxib will be given at the dose of 400 mg BID for total of 12 months. Patients will be advised to take this medication with food to improve absorption.

Locations

Country	Name	City	State
United States	Ohio State University Comrehensive Cancer Center	Columbus	Ohio
United States	University of Texas - MD Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Ohio State University Comprehensive Cancer Center

Country where clinical trial is conducted

United States, 

References & Publications (1)

Mrozek E, Kloos RT, Ringel MD, Kresty L, Snider P, Arbogast D, Kies M, Munden R, Busaidy N, Klein MJ, Sherman SI, Shah MH. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2006 Jun;91(6):2201-4. Epub 200 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Examine efficacy of celecoxib in patients with progressive metastatic differentiated thyroid carcinoma by assessing progression free survival.		up to 12 months following treatment	Yes
Secondary	Quantifying gene expression and protein levels of angiogenic markers[vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and tumor necrosis factor (TNF)-a] in peripheral blood mononuclear cells (PBMCs) from pre-,during-		pre-study, every eight weeks and off study	No
Secondary	Quantifying gene expression and protein levels of cytokines [interleukin (IL)-10, IL-12, IL-6 and interferon (IFN)-?] in peripheral blood mononuclear cells from pre-,during-, and post-treatment blood samples.			No
Secondary	Evaluate cyclooxygenase (COX)-2 protein expression by immunohistochemistry in tumor biopsies to correlate with clinical response.			No

External Links

•   Jamesline